Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 1, 2005
Quinn will be responsible for Company-wide human resources efforts, supporting all businesses, regions and functions.
-
May 25, 2005
The Company announced the estimates at a meeting of financial analysts held in conjunction with the Paris Course on Revascularization (EuroPCR).
-
May 25, 2005
TAXUS V trial is studying the most challenging lesions and highest-risk patients ever studied in a randomized, controlled clinical trial in the United States.
-
May 25, 2005
Thirty-day safety data reported from global ATLAS clinical trial.
-
May 25, 2005
Clinical findings announced at the annual Paris Course on Revascularization.
-
May 24, 2005
Two-year follow-up data from TAXUS VI clinical trial consistent with results for slow-release TAXUS formulation.
-
May 24, 2005
Results presented are among the most comprehensive intravascular ultrasound (IVUS) follow-up data of any drug-eluting stent randomized clinical trial.
-
May 23, 2005
Research may signal new hope for the estimated 18.8 million Americans suffering from depression and four million from AD.
-
May 23, 2005
Extended expiration date applies to all sizes of the TAXUS system for sale in the United States.
-
May 20, 2005
The Paris Course on Revascularization (EuroPCR) runs from May 24 to 27; read the schedule highlights.